Chimerix Inc (CMRX)
0.9452
+0.01
(+1.13%)
USD |
NASDAQ |
Apr 30, 14:03
Chimerix Cash and Short Term Investments (Quarterly): 182.84M for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 182.84M |
September 30, 2023 | 194.48M |
June 30, 2023 | 205.76M |
March 31, 2023 | 214.75M |
December 31, 2022 | 217.33M |
September 30, 2022 | 284.63M |
June 30, 2022 | 42.79M |
March 31, 2022 | 53.38M |
December 31, 2021 | 88.37M |
September 30, 2021 | 122.56M |
June 30, 2021 | 132.03M |
March 31, 2021 | 144.98M |
December 31, 2020 | 78.96M |
September 30, 2020 | 87.76M |
June 30, 2020 | 95.95M |
March 31, 2020 | 103.02M |
December 31, 2019 | 113.48M |
September 30, 2019 | 116.72M |
June 30, 2019 | 158.40M |
March 31, 2019 | 171.59M |
December 31, 2018 | 186.53M |
September 30, 2018 | 183.36M |
June 30, 2018 | 174.76M |
Date | Value |
---|---|
March 31, 2018 | 160.45M |
December 31, 2017 | 151.52M |
September 30, 2017 | 149.72M |
June 30, 2017 | 148.53M |
March 31, 2017 | 161.70M |
December 31, 2016 | 232.02M |
September 30, 2016 | 249.67M |
June 30, 2016 | 272.82M |
March 31, 2016 | 263.34M |
December 31, 2015 | 220.33M |
September 30, 2015 | 220.80M |
June 30, 2015 | 258.33M |
March 31, 2015 | 174.50M |
December 31, 2014 | 234.58M |
September 30, 2014 | 188.42M |
June 30, 2014 | 200.60M |
March 31, 2014 | 99.92M |
December 31, 2013 | 109.98M |
September 30, 2013 | 116.90M |
June 30, 2013 | 123.03M |
March 31, 2013 | 22.92M |
December 31, 2012 | 29.76M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
42.79M
Minimum
Jun 2022
284.63M
Maximum
Sep 2022
138.85M
Average
122.56M
Median
Sep 2021
Cash and Short Term Investments (Quarterly) Benchmarks
UFP Technologies Inc | 5.263M |
Dentsply Sirona Inc | 334.00M |
Arbutus Biopharma Corp | 126.00M |
Pacira BioSciences Inc | 278.58M |
Karyopharm Therapeutics Inc | 191.44M |